Pediatric Blood & CancerOccurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

ℹ️ Observational Association Only Evidence

Researchers analyzed 167 relapses among 90 pediatric patients. Blinatumomab exposure was associated with other extramedullary relapse, including disease without concurrent marrow involvement.

Clinical Considerations

• Other extramedullary disease occurred in 30.4% of relapses after blinatumomab versus 6.9% without prior exposure.
• Blinatumomab was associated with OEMR after adjustment for transplantation, graft-versus-host disease, and total-body irradiation.
• The isolated OEMR estimate carried a wide confidence interval, reflecting few events and substantial statistical uncertainty.
• Retrospective treatment selection and overlapping immunotherapies limit causal interpretation.

Practice Applications

• Recognize atypical organ, bone, lymphatic, renal, ocular, or soft-tissue relapse presentations.
• Consider extramedullary disease when symptoms emerge despite negative marrow findings.
• Interpret this association as hypothesis-generating, not proof of treatment causality.
• Monitor emerging prospective evidence before changing surveillance protocols.